INTRODUCTION
============

Peri- and intra-operative shivering induces patient discomfort due to severe muscle movements, and it also causes tachycardia and hypertension. This eventually leads to increased carbon dioxide synthesis and increased oxygen consumption, which results in an increased cardiac workload and pulmonary ventilation capacity. It also leads to an increase in the metabolic rate by up to 400% \[[@B1]\].

Spinal anesthesia can be quickly and simply induced, and due to its fewer systemic complications, it is more advantageous than general anesthesia. Likewise, spinal anesthesia is vastly used for cesarean section \[[@B2],[@B3]\]. In spinal anesthesia for cesarean section, the anesthetized area (the sympathetic nerve innervated in the lower limbs) is blocked. From the center of the body to the periphery, this blockage redistributes the body heat. Hence, the afferent temperature signal in the anesthetized area is not transmitted to thermoregulation center which is located in the hypothalamus. This leads to a disruption in normal temperature regulation, resulting in increased shivering and a decreased core temperature \[[@B4],[@B5]\]. Shivering related to spinal anesthesia is a frequent complication, and the median incidence of shivering associated with neuraxial anesthesia is reported to be as high as 56% \[[@B6]\]. Those effects are principally bothersome in an obstetrical population \[[@B7]\]. Therefore, it is important to prevent the incidence of shivering during spinal anesthesia.

Intravenous administration of drugs including magnesium sulfate, clonidine, meperidine, physostigmine, and ketanserin has been suggested for the treatment of shivering \[[@B8],[@B9]\]. Of these, meperidine seems to be the most effective agent for the treatment of shivering \[[@B10]\]. Meperidine is a κ (Kappa)-receptor agonist and opioid µ (Mu)-receptor that reduces the threshold of vascular constriction which is known to effectively treat shivering \[[@B11]\].

During last decade, some studies have reported the positive effects of different doses of intrathecal meperidine during spinal anesthesia on reducing the severity and incidence of perioperative shivering \[[@B12]-[@B14]\]. Intravenous meperidine is widely used for the treatment of shivering intra-operatively (during the cesarean section) and post-operatively (in the recovery room) but it could be associated with side effects. In addition, use of high doses of intrathecal meperidine may have similar side effects such as nausea, vomiting, respiratory distress and pruritus. Adding meperidine to the intrathecal hyperbaric bupivacaine fusion during spinal anesthesia reduces the incidence and severity of shivering shown in obstetrical populations undergoing cesarean delivery \[[@B15],[@B16]\].

Different doses of intrathecal meperidine have been used to prevent shivering during spinal anesthesia \[[@B14],[@B15],[@B17]\]. However, there is a consensus concerning the optimal dose. Given this background, with a local anesthetic, we administered an intrathecal infusion of low dose meperidine for spinal anesthesia in women who were undergoing cesarean section. Then, we evaluated the effects of this type of treatment on the inhibition of shivering in patients during spinal anesthesia.

MATERIALS AND METHODS
=====================

This study was performed at the anesthetic clinic of Peymanie hospital, a tertiary health center affiliated with Jahrom University of Medical Sciences. We enrolled 100 parturients (ASA physical status I or II) who were scheduled for elective cesarean delivery under spinal anesthesia ranging in age from 18-40 years between April and December of 2012 ([Fig. 1](#F1){ref-type="fig"}). The review board of Jahrom University of Medical Sciences approved the study protocol and all the enrolled parturients completed an informed consent form. None of the patients had a history of contraindication to spinal anesthesia and cesarean section surgery, sever preeclampsia, hypo or hyperthyroidism, Reynaud\'s syndrome, preoperative body temperature \> 38℃, a height \< 152 cm, and allergies to the study medications (meperidine and lidocaine).

Parturients were given a sealed envelope that included their admission number by an assistant who was blinded to the study. This admission number was the participant\'s medical chart number. A physician who was blinded to the study opened the envelopes in the order of presentation and gave the parturients a black box if they had an even number and a white box if they had an odd number. The participants with odd numbers (n = 50) were assigned to the 5% mepridine 0.2 ml (Pethidine®, Hana Pharmaceutical Corp, Korea; no preservative) (0.2 mg/kg) plus hyperbaric lidocaine (Actavis, Zug, Switzerland) (5%, 75 mg, n = 50; group M) group and those with even numbers (n = 50) were assigned to the equivalent volume of placebo (sterile saline) plus hyperbaric lidocaine (5%, 75 mg, n = 50; group L) group. Before performing spinal anesthesia, patients were monitored for blood pressure (BP), heart rate (HR), electrocardiogram, and oxygen saturation, and received intravenous warmed (37℃) lactated Ringer\'s solution 10 ml/kg. Through a Hudson mask, oxygen was given during anesthesia, and parturients were covered with a layer of surgical drapes over the clavicles, chest and thighs but not actively warmed. An anesthesiologist who was blinded to the study performed the spinal block. With a 25-G Quincke needle in the sitting position at the inter space of L3-L4, spinal anesthesia was performed. After spinal injection, patients were placed in the supine position with a left lateral tilt.

T0 was determined as the time at the end of the injection. By using pinpricks, the sensory block was evaluated every 5 min during the first 40 min and then every 10 min thereafter. The level of segment blocked was evaluated during operation and in the post-anesthesia care unit (PACU). A blinded trained anesthesiology resident evaluated the grades of shivering intensity \[[@B18]\] every 5 min during the intra- and post-operative periods: 0, no shivering; 1, peripheral, piloerection vasoconstriction, or both are present but no visible shivering; 2, muscular activity in only one muscle group; 3, muscular activity in more than one muscle group but no generalized shivering (moderate muscular activity); 4, shivering involving the whole body (violent muscular activity). To prevent unwanted complications in the mother and fetus, shivering was stopped with IV clonidine (0.5 µg/kg) after evaluating the shivering intensity in both groups.

Systolic and diastolic BP and HR were measured before, immediately after, and at 5, 15, 30, and 60 minutes after spinal anesthesia. Simultaneously, while recording the shivering intensity, a blinded observer recorded the peripheral and core temperature, peripheral oxygen saturation, and intrathecal opioid-related side effects. Arterial hypotension was defined as a decrease in systolic blood pressure \< 90 mmHg or less than 25% of the baseline value. Hypotension and HR \< 50 were treated with intravenous ephedrine 5 mg and intravenous atropine 0.5 mg, respectively. If nausea, vomiting, and pruritus occurred during the operation and in the PACU, they were noted. We administered intravenous metoclopramide 10 mg in patients with nausea and vomiting during or after spinal anesthesia. Respiratory depression (SpO2 less than 95%) was supported with active ventilation in both groups. Apgar .scores at 1 and 5 minutes and surgery duration were also recorded by a blinded observer.

Based on the preliminary study, a power analysis was done to find a sufficient sample size in determining a significant difference in the intensity of shivering by using an alpha value of 0.05 and a power of 80%. The intensity of shivering was 65% in the meperidine group and 25% in the control in the preliminary study. This established that a sample size of twenty four patients was adequate per group. We enrolled 50 parturients in each group to compensate for possible none valuable data. The Statistical Package for Social Science (SPSS) for Windows, version 14 (SPSS Inc., Chicago, IL) was used for data analysis. Paired T-tests were used to compare results within the groups; independent T-tests were used to compare results between the groups; X^2^ tests tests were used to compare proportions. Data are reported as the means ± SD for 95% confidence interval (CI) with 5% degree of freedom. A two-sided *P* value \< 0.05 was considered statistically significant.

RESULTS
=======

All of the participants successfully finished the study. According to [Table 1](#T1){ref-type="table"}, the time to reach the highest block in the meperidine group was significantly lower than that of the controls (*P* = 0.01). There were no significant differences in vital signs between the two groups during the entire study period. The demographic and surgical data of the 2 study groups are presented in [Table 1](#T1){ref-type="table"}. All baseline measurements were comparable between the two groups.

The mean systolic pressure was 121.0 ± 14.6 in the L group and 121.8 ± 11.5 in the M group, prior to spinal anesthesia; nevertheless, the systolic pressure immediate after and at 5, 15, 30, and 60 minutes after the spinal anesthesia significantly decreased compared to the baseline in the 2 study groups (*P* \< 0.05) ([Fig. 2](#F2){ref-type="fig"}). Prior to spinal anesthesia, the mean diastolic pressure was 80.7 ± 9.5 in the L group and 80.5 ± 7.2 in the M group; nevertheless, the diastolic pressure at 5, 15, 30, and 60 minutes after the spinal anesthesia significantly decreased compared to the baseline in both groups (*P* \< 0.05) ([Fig. 3](#F3){ref-type="fig"}). There were six patients in group L and seven patients in group M who were given ephedrine. No significant difference in heart rate between the two groups was observed ([Fig. 4](#F4){ref-type="fig"}).

Significant debilitation of shivering was seen in parturients having received meperidine, and the results obtained were statistically significant ([Fig. 5](#F5){ref-type="fig"}, *P* = 0.04). According to the grade of shivering, of the four parturients in the M group who experienced shivering, three were Grade 1, one was Grade 2 and no parturients were Grades 3 and 4. Of the 14 parturients in the L group who presented with shivering, three were Grade 1, two were Grade 2, five were Grade 3, and four were Grade 4 ([Fig. 6](#F6){ref-type="fig"}).

There were no significant differences in nausea and vomiting between the meperidine group and the controls ([Table 2](#T2){ref-type="table"}, *P* \> 0.05). Clonidine was used as a rescue for shivering treatment for 4 parturients in the meperidine group and 14 parturients in the controls. The apgar scores were similar between the two study groups (*P* \> 0.05).

DISCUSSION
==========

According to the data, adding a small dose of meperidine (0.2 mg/kg) to the intrathecal mixture of anesthesia reduces the intensity of shivering in an obstetric population undergoing spinal anesthesia for cesarean section. And the use of intrathecal meperidine at the doses used in this study does not significantly increase unwanted adverse effects such as nausea, vomiting, hypotension, bradycardia, tachycardia, and pruritus.

Spinal anesthesia is widely used for cesarean section. Spinal anesthesia causes well established side effects such as headache, dysuria, nausea, and vomiting, for which treatment has been considerably examined to date. Shivering is another side effect which is defined as an involuntary movement of muscles that can cause discomfort in patients. In some cases, postoperative pain may stimulate the development of shivering \[[@B19]\]. For the safety of patients, perioperative monitoring of vital signs such as body temperature is necessary. Particularly, the management of body temperature following aneasthesia is closely related to patient status and postoperative outcome. The perioperative occurrence of shivering may increase the intracranial pressure \[[@B20]\], intraocular pressure \[[@B21]\], oxygen consumption and complicate the use of a monitor \[[@B22]\] and increase the synthesis of carbon dioxide by three-fold. Therefore, an increase in metabolic demand induces difficulties in patients with intrapulmonary compartments, limited pulmonary capacity, and a fixed cardiac output \[[@B23]\].

The mechanism by which shivering develops is still unclear. The etiology of shivering is supposed to be heat loss throughout the anesthesia and surgery. However, there is a critical dispute encompassing the incidence of hypothermia due to heat loss. Jones and McLaren \[[@B24]\] showed that the occurrence of postoperative shivering was related to the decrease in body temperature which is measured through the esophagus. However, in contrast to the reports of Jones and McLaren, Pflug et al. \[[@B25]\] reported no significant differences in core temperature between both groups of patients who experienced shivering and those who did not. In our study, no significant difference in core temperature was observed between the study groups.

Several hypotheses have been stated to describe the incidence of postoperative shivering \[[@B26],[@B27]\] including the following: (1) loss of thermoregulatory vasoconstriction beneath the level of the anesthetized region, resulting in increased heat loss from the body surface due to the excessive thermogenesis; (2) redistribution of body or heat temperature, where core and peripheral temperatures are generated because of the redistribution of heat from the center to the periphery due to temperature differences; and (3) altered thermoregulation because of a mild increase in the sweating threshold and a small decrease in vasoconstriction.

As described previously, the etiology of shivering has not been completely elucidated, but it likely involves multiple etiologies. The treatment regimens for shivering are not fully established despite the various numbers of studies on shivering. Common treatment regimens for shivering conclude warming the body temperature, increasing the operating room temperature, and using drugs such as clonidine, meperidine, fentanyl, morphine, butophanol, malbuphine, doxapram, ketanserine, and taurine \[[@B8],[@B28]\].

Of the above mentioned treatment procedures, an intravenous infusion of meperidine is supposed to be the gold standard treatment. In comparison to other opioids, meperidine has a considerable antishivering effect; therefore, it is widely used to prevent and treat shivering \[[@B29]\]. Many studies have revealed that meperidine has a greater antishivering effect than a similar dose of fentanyl or morphine, with its affinity for µ - receptors. Likewise, it can be inferred that the greater antishivering effect of meperidine over other analgesic drugs is because of its affinity for the κ - receptor. Up to now, it has not been fully elucidated by which mechanism meperidine mediates its antishivering effect. With regard to some clinical studies, meperidine slightly increases the threshold for sweating, significantly decreases the threshold for vasoconstriction, and reduces the threshold for shivering \[[@B30]\].

As described previously, an intravenous infusion of meperidine induces no pain despite its intramuscular infusion; therefore, it is very effective in the treatment and prevention of shivering. Unexpected side effects such as pruritis, bronchospasm, hypotension, bradycardia, respiratory insufficiency, nausea, and vomiting may be associated with an intravenous infusion of meperidine. Alternatively, an intrathecal infusion of meperidine can minimize these side effects \[[@B7]\]. Our data showed that the time to reach the highest block in the meperidine group was significantly lower than that of the controls; this effect may be proportionate to a low level dose of meperidine. Accordingly, these results show that meperidine added to hyperbaric lidocaine does not prolong the total anesthesia time.

However a single use of meperidine (0.5-1.5 mg/kg) for spinal anesthesia has a strong effect as a local anesthetic, but a higher dose of meperidine (50 mg) is associated with respiratory depression in a dose-dependent manner \[[@B17]\]. In our study, due to the low dose of meperidine (0.2 mg/kg), respiratory depression did not occur. Moreover, there were no significant differences between the two studied groups in the comparison of the maximum height of sensory block.

In conclusion, the data of this study suggest that an intrathecal infusion of a low dose of meperidine included in a local anesthetic does not affect the height of the sensory block, prevents the occurrence of shivering, and minimizes the occurrence of unexpected side effects related to an intravenous infusion of meperidine.
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![Participation flow chart.](kjpain-26-379-g001){#F1}

![Changes in mean systolic pressure between groups L and M. Each bar represents the mean ± SD. Group L (n = 50) received spinal anesthesia that consisted of hyperbaric lidocaine (5%, 75 mg) and normal saline. Group M (n = 50) received spinal anesthesia that consisted of hyperbaric lidocaine (5%, 75 mg) and meperidine (0.2 mg/kg). There were no significant differences between group L and M. ^\*^*P* \< 0.05: Compared to pre-operative values within each group.](kjpain-26-379-g002){#F2}

![Changes in mean diastolic pressure between groups L and M. Each bar represents the mean ± SD. Group L (n = 50) received spinal anesthesia that consisted of hyperbaric lidocaine (5%, 75 mg) and normal saline. Group M (n = 50) received spinal anesthesia that consisted of hyperbaric lidocaine (5%, 75 mg) and meperidine (0.2 mg/kg). There were no significant differences between group L and M. ^\*^*P* \< 0.05: Compared to pre-operative values within each group.](kjpain-26-379-g003){#F3}

![Changes in heart rate between groups L and M. Each bar represents the mean ± SD. Group L (n = 50) received spinal anesthesia that consisted of hyperbaric lidocaine (5%, 75 mg) and normal saline. Group M (n = 50) received spinal anesthesia that consisted of hyperbaric lidocaine (5%, 75 mg) and meperidine (0.2 mg/kg). There were no significant differences between group L and M.](kjpain-26-379-g004){#F4}

![The incidence of shivering. The incidence of shivering was significantly lower in group M than in group L (*P* \< 0.05).](kjpain-26-379-g005){#F5}

![The intensity of shivering for each patient; 0, no shivering; 1, peripheral, piloerection vasoconstriction, or both are present but no visible shivering; 2, muscular activity in only one muscle group; 3, muscular activity in more than one muscle group but no generalized shivering (moderate muscular activity); 4, shivering involving the whole body (violent muscular activity). There were significant differences in the intensity of shivering between groups L and M (*P* \< 0.05).](kjpain-26-379-g006){#F6}

###### 

The Demographic and Surgery Data During the Whole Time of the Study Period (Data Are Expressed as Mean ± SD)
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BMI: body mass index, SBP: systemic blood pressure, DBP: diastolic blood pressure. ^\*^L: control group, M: case group.

###### 

Adverse Effects of the Two Study Groups During the Whole Time of the Study Period
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NS: not significant. ^\*^L: control group, M: case group. ^†^Frequency (percentage) is reported.
